Navigation Links
Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today
Date:1/16/2008

LA JOLLA, Calif., Jan. 16 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) did not authorize or endorse the release of an Equity Research Profile on the company issued by Proteus Equity Research Partners, a privately-held equity research company, nor the associated press release announced earlier today.

Further, The Blaine Group is the only authorized public and investor relations firm retained by Immunosyn Corporation at this time.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more information on Immunosyn and SF-1019 go to http://www.immunosyn.com)

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not gu
'/>"/>

SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Private Equitys Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference
2. MB Software Corporation Reaches Agreement with Keystone Equity Partners
3. Private Equity Firms Acquire American Laser Centers
4. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
5. Health Fitness Announces Non-Cash Adjustment and Restatement of 2006 Equity Investment Transaction Resulting in Delay for Filing Third Quarter Form 10-Q
6. Harmony Information Systems Raises $28 Million in Series B Financing from JMI Equity, Updata Partners, ORIX Venture Finance and Comerica Bank
7. StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR) Review Issued By Scimitar Equity Research, Inc.
8. SEIU Applauds Bipartisan Leadership of Sen. Finance Committee in Push for Greater Oversight of Private Equity Takeovers of Nursing Homes
9. Conseco Completes Divestiture of Old Block of Fixed and Equity-Indexed Annuities
10. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
11. With the Largest-Ever Buyout of a National Nursing Home Chain Pending ... New York Times Exposes Harm to Seniors After Private Equity Buyouts of Nursing Homes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
... boy from Indonesia had a tumor measuring about 7....or made up around 10% of his body weight.// The tu...ingapore at Mount Elizabeth Hospital involving dif...eloped due to an Iodine deficiency which is an end...
... Brian Jago, from the UK has said that he is being...lable in Wales and Scotland.// Jago has been diagn...n July 2003. He has undergone a stem cell transpla...iled to check the disease. The Southampton Univer...
...nges the one accepted truism of dietary research s...inst colorectal cancer.// The latest analysis of ...od with high fibre content such as cereals, vegeta...to get colon cancer, fiber-cancer association is w...
... the progression of chronic myelogenous leukemia (...ientists. They have also found out that an extract...is called forskolin can be used for suppressing th...e are expected to develop CML this year, and the f...
Other Medicine News:Health News:Study finds no link between fibre and cancer risk 2
(Date:8/25/2008)...lls Found in Menstrual Blood May Offer Long-Lastin...ed Women, OLDSMAR, Fla., Aug. 25 /- ...ould agree that there never seems to be enough,of ... doing something just,for herself usually pales in...s reality has led many women in need of quality ti...
(Date:8/25/2008)...s., Aug. 25 /- Joseph F. Finn, Jr.,C..., Inc. ("Spherics") for,the benefit of creditors, ...al property will be sold at a sealed bid auction o...se formulation of Levodopa-Carbidopa that,is the c...ease, with global,sales estimated at approximately...
(Date:8/25/2008)...ug. 25 /- Anthera Pharmaceuticals,Inc...loping,anti-inflammatory drugs, today announced th... coronary events with Near-term Cardiovascular,Inf...examine the impact of,varespladib when administere... Syndrome (ACS) event., The FRANCIS trial is desi...
(Date:8/22/2008)... in Trial Sponsored by Medical Research Council, ...- Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) a...tocol MDP 301, a Phase III clinical trial of PRO 2...or the prevention of HIV and other,sexually transm...ited,Kingdom,s Medical Research Council (MRC) and ...
Breaking Medicine Technology:Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits 2Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 3Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 2Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 3Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 4Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 5Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 842 1Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 842 2Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 842 3Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference 28ECCO 29 395 1Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference 28ECCO 29 395 2Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference 28ECCO 29 395 3Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference 28ECCO 29 395 4Heart Attack Survivors Benefit From Rehab 2063 1Heart Attack Survivors Benefit From Rehab 2063 2Mixing large doses of both acetaminophen painkiller and caffeine may increase risk of liver damage 568 1Mixing large doses of both acetaminophen painkiller and caffeine may increase risk of liver damage 568 2
... Researchers at,Molecular Insight Pharmaceuticals ...ta on MIP-1072, a radiolabeled, small molecule,mol...iagnosis and,staging of prostate cancer at the 54t...e (SNM) in Washington, D.C. MIP-1072 is,one of two...sis,that Molecular Insight plans to advance into e...
...Corporation,(NASDAQ: CYTO) today reported results ...(samarium Sm-153 lexidronam injection),can be safe...e also,receiving the chemotherapy docetaxel (Taxot...t further evaluation of the combination,regimen fo...ogram.,The results were presented and/or published...
Other Medicine Technology:Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 2Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 3Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 2New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 3New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 5New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 6New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 7
...ons about insulin dosages and other medication, ab...ed by data from blood glucose tests and other rele...seen by you and your Health Care Providers when th...mats. The FreeStyle CoPilot System makes the data ...
... Photocoagulator.,Retinal physicians throughout ...is multi-color photocoagulators.,For the retinal...integrates green, yellow, and red solid-state,d...hat supports your treatment of a diverse range of ...
... Photocoagulator.,Retinal physicians throughout ...is multi-color photocoagulators.,For the retinal...integrates green, yellow, and red solid-state,d...hat supports your treatment of a diverse range of ...
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction.
Medicine Products: